Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lifeline for cancer patients: rollover study extends access to targeted drug opnurasib

NCT ID NCT07468071

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 4 times

Summary

This rollover study allows up to 40 people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from opnurasib in a Novartis trial to keep receiving the drug. Participants continue their current dose of opnurasib alone or with TNO155 or trametinib. The goal is to provide ongoing treatment access and monitor long-term safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
opnurasib (JDQ443) alone or with TNO155 or trametinib
What this could lead to
If successful, this study shows that long-term use of opnurasib is safe and helps control KRAS G12C-mutated cancers.
What could go wrong
This is a small rollover study (40 people) with no control group, so it cannot prove the drug works better than other options. Side effects may still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS HARBORING THE KRAS G12C MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS HARBORING THE KRAS G12C MUTATION LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Sint-Niklaas, Oost Vlaanderen, 9100, Belgium

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Novartis Investigative Site

    RECRUITING

    Guangzhou, Guangdong, 510080, China

  • Novartis Investigative Site

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • Novartis Investigative Site

    RECRUITING

    Koto Ku, Tokyo, 1358550, Japan

  • Novartis Investigative Site

    RECRUITING

    Kuching, Sarawak, 93586, Malaysia

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Seoul, 03080, South Korea